Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial

被引：0
|
作者：
Tetsu Hayashida
Hiromitsu Jinno
Katsuaki Mori
Hiroki Sato
Akira Matsui
Takashi Sakurai
Hiroaki Hattori
Shin Takayama
Masahiro Wada
Maiko Takahashi
Hirohito Seki
Tomoko Seki
Aiko Nagayama
Akiko Matsumoto
Yuko Kitagawa
机构：
[1] Keio University School of Medicine,Department of Surgery
[2] Teikyo University School of Medicine,Department of Surgery
[3] Hino Municipal Hospital,Department of Surgery
[4] Mito Red Cross Hospital,Department of Surgery
[5] National Hospital Organization Tokyo Medical Center,Department of Surgery
[6] JCHO Saitama Medical Center,Division of Surgery
[7] Federation of National Public Service Personnel Mutual Aid Associations,Department of Surgery
[8] Tachikawa Hospital,Department of surgery
[9] Tokyo Dental College Ichikawa General Hospital,Department of Surgery
[10] Sanokousei general hospital,undefined
来源：
BMC Cancer | / 18卷
关键词：
Breast cancer; Eribulin; Phase II trial;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Gemcitabine plus paclitaxel and gemcitabine plus docetaxel in first- or second-line metastatic breast cancer: A phase II randomized trial
    Boccia, R. V.
    Vaughn, L.
    Zeigler, H.
    Wang, Y.
    Gill, J.
    Melemed, A.
    Shonukan, O.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [22] Pyrotinib in combination with docetaxel as first-line treatment for HER2-positive metastatic breast cancer (PANDORA): A single-arm, multicenter phase II trial
    Wang, X.
    Huang, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S646 - S647
  • [23] Eribulin mesylate plus trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer: results from a phase 2, multicenter, single-arm study
    Vandat, L.
    Schwartzberg, L.
    Wilks, S.
    Rege, J.
    Liao, J.
    Cox, D.
    O'Shaughnessy, J.
    CANCER RESEARCH, 2012, 72
  • [24] Eribulin as first-line treatment in older patients with advanced breast cancer: A multicenter phase II trial [SAKK 25/14]
    Hasler-Strub, Ursula
    Mueller, Andreas
    Li, Qiyu
    Thuerlimann, Beat
    Ribi, Karin
    Gerber, Stefan
    von Moos, Roger
    Fehr, Mathias
    Rochlitz, Christoph
    Zaman, Khalil
    Aebi, Stefan
    Hochstrasser, Andreas
    Gick, Ute
    Baertschi, Daniela
    Greuter, Stefan
    Schreiber, Alexander
    Caspar, Clemens B.
    Trojan, Andreas
    Condorelli, Rosaria
    Ruhstaller, Thomas
    JOURNAL OF GERIATRIC ONCOLOGY, 2023, 14 (01)
  • [25] Effectiveness of bevacizumab in first- and second-line treatment for metastatic colorectal cancer: ITACa randomized trial
    Petracci, Elisabetta
    Scarpi, Emanuela
    Passardi, Alessandro
    Biggeri, Annibale
    Milandri, Carlo
    Vecchia, Stefano
    Gelsomino, Fabio
    Tassinari, Davide
    Tamberi, Stefano
    Bernardini, Ilaria
    Accettura, Caterina
    Frassineti, Giovanni Luca
    Amadori, Dino
    Nanni, Oriana
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [26] Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study
    Ortega, Vanesa
    Anton, Antonio
    Garau, Isabel
    Afonso, Nomia
    Calvo, Lourdes
    Fernandez, Yolanda
    Martinez-Garcia, Maria
    Blanco, Esperanza
    Zamora, Pilar
    Garcia, Mirta
    Juan Illarramendi, Jose
    Rodriguez Sanchez, Csar Augusto
    Sampayo, Miguel
    Aguirre, Elena
    Manuel Perez-Garcia, Jose
    Cortes, Javier
    Llombart-Cussac, Antonio
    CLINICAL BREAST CANCER, 2019, 19 (02) : 105 - 112
  • [27] Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: A prospective randomized trial
    Joensuu, H
    Holli, K
    Heikkinen, M
    Suonio, E
    Aro, AR
    Hietanen, P
    Huovinen, R
    JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (12) : 3720 - 3730
  • [28] Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial
    Chen, Yajin
    Du, Chengyou
    Shen, Shunli
    Zhang, Wu
    Shan, Yunfeng
    Lyu, Ang
    Wu, Jianhui
    Shang, Changzhen
    Luo, Xuan
    Wei, Jinxing
    Xiao, Heng
    Qiu, Jianguo
    Hua, Yunpeng
    Wang, Shutong
    Wang, Ting
    Dai, Shengjie
    Zhang, Shuhao
    Xie, Bingying
    Wu, Yinghao
    Hao, Chunyi
    CLINICAL CANCER RESEARCH, 2024, 30 (14) : 2937 - 2944
  • [29] Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: A prospective randomized trial
    Tanner, J
    Dunst, J
    STRAHLENTHERAPIE UND ONKOLOGIE, 1999, 175 (09) : 471 - 471
  • [30] Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer
    Ross, Helen J.
    Blumenschein, George R., Jr.
    Aisner, Joseph
    Damjanov, Nevena
    Dowlati, Afshin
    Garst, Jennifer
    Rigas, James R.
    Smylie, Michael
    Hassani, Habib
    Allen, Kimberly E.
    Leopold, Lance
    Zaks, Tal Z.
    Shepherd, Frances A.
    CLINICAL CANCER RESEARCH, 2010, 16 (06) : 1938 - 1949
12345